Current Opinion in Oncology最新文献_第9页

Insights from the brain connectome in patients with gliomas. 神经胶质瘤患者脑连接组的研究。

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2025-11-01 Epub Date: 2025-08-26 DOI: 10.1097/CCO.0000000000001190

Alessandro Salvalaggio, Giulio Sansone, Lorenzo Pini, Maurizio Corbetta

{"title":"Insights from the brain connectome in patients with gliomas.","authors":"Alessandro Salvalaggio, Giulio Sansone, Lorenzo Pini, Maurizio Corbetta","doi":"10.1097/CCO.0000000000001190","DOIUrl":"10.1097/CCO.0000000000001190","url":null,"abstract":"Purpose of review: Recent preclinical studies have demonstrated that gliomas interact with the brain at the synaptic level, influencing tumor progression. These local interactions have broader effects on the brain's structural and functional connectivity. This review summarizes recent findings on how brain-glioma interactions impact the brain connectome and explores their clinical implications.Recent findings: Glioma progression and brain connectivity are interdependent. Functional connectivity changes in glioma patients are observed across the entire brain and are associated with overall survival. Gliomas tend to develop in highly connected brain hubs, which have higher metabolic demands. Structurally, glioblastoma cells preferentially spread along white matter tracts, with tumours located in regions of dense white matter being linked to shorter survival. Moreover, functional network reorganization in glioma patients correlates with cognitive function and involves widespread areas, including the contralateral hemisphere.Summary: Measures derived from the brain connectome offer promising prognostic value and deepen our understanding of glioma growth and dissemination mechanisms.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"595-602"},"PeriodicalIF":2.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145243856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Measurable residual disease as an actionable biomarker in acute myeloid leukemia. Ready or not? 可测量的残留疾病作为急性髓系白血病可操作的生物标志物。准备好了吗?

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2025-11-01 Epub Date: 2025-09-24 DOI: 10.1097/CCO.0000000000001197

Francesco Buccisano, Raffaele Palmieri, Federico Moretti, Elisa Meddi, Ilaria Cerroni, Adriano Venditti

{"title":"Measurable residual disease as an actionable biomarker in acute myeloid leukemia. Ready or not?","authors":"Francesco Buccisano, Raffaele Palmieri, Federico Moretti, Elisa Meddi, Ilaria Cerroni, Adriano Venditti","doi":"10.1097/CCO.0000000000001197","DOIUrl":"10.1097/CCO.0000000000001197","url":null,"abstract":"Purpose of review: Measurable residual disease (MRD) is a reliable biomarker measuring the quality of morphological complete remission in acute myeloid leukemia (AML). This review will illustrate the settings where, along with drug development, MRD monitoring is by itself an actionable therapeutic target and represents not only a prognostic marker but a predictive marker of response, prompting a further relevant progress toward personalized medicine.Recent findings: The double nature of certain biomarkers (e.g. PML/RARA , bcr/abl , FLT3 , IDH1/2 , NPM1 ), useful for MRD monitoring and key actors in AML development, has emerged. The use of targeted drugs (e.g. FLT3 inhibitors, IDH1/2 inhibitors) or drug combination that are particularly active in specific AML subsets (e.g. Azacytidine/Venetoclax in NPM1 mutated AML), has paved the way to clinical trial experimenting maintenance or preemptive treatment driven by MRD persistence or reappearance.Summary: Accurate and specific MRD monitoring, coupled with the increasing development of targeted drugs, will give to clinicians an extraordinary opportunity to anticipate the treatment of AML relapse in the early phases eventually increasing drug efficacy and long-term outcome of the patients (visual abstract).","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"618-624"},"PeriodicalIF":2.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145198578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunotherapy in the neoadjuvant treatment of hormone receptor-positive/HER2-negative early breast cancer: novel approaches and future perspectives. 免疫疗法在激素受体阳性/ her2阴性早期乳腺癌新辅助治疗中的应用：新方法和未来展望

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2025-11-01 Epub Date: 2025-08-07 DOI: 10.1097/CCO.0000000000001183

Luca Arecco, Gabriella Gentile, Riccardo Gerosa, Matteo Lambertini, Laurence Buisseret, Alex De Caluwé, Evandro de Azambuja

{"title":"Immunotherapy in the neoadjuvant treatment of hormone receptor-positive/HER2-negative early breast cancer: novel approaches and future perspectives.","authors":"Luca Arecco, Gabriella Gentile, Riccardo Gerosa, Matteo Lambertini, Laurence Buisseret, Alex De Caluwé, Evandro de Azambuja","doi":"10.1097/CCO.0000000000001183","DOIUrl":"10.1097/CCO.0000000000001183","url":null,"abstract":"Purpose of review: To summarize recent advances and emerging strategies for integrating immunotherapy into the neoadjuvant treatment of patients with hormone receptor (HR)-positive/HER2-negative early breast cancer (eBC). This review explores how combining immune checkpoint inhibitors (ICIs) with standard treatments and/or novel strategies may potentially improve responses and long-term outcomes.Recent findings: Recent clinical trials have demonstrated that adding ICIs to standard neoadjuvant chemotherapy in HR-positive eBC significantly increases pathological complete response (pCR) rates. However, this benefit should be balanced against an increase in side effects, particularly those immune-mediated. Innovative approaches, such as incorporating radiation therapy to neoadjuvant treatments and ICIs have shown promise in enhancing immune responses, potentially overcoming the lower immunogenicity of luminal-like eBC.Summary: The integration of immunotherapy into neoadjuvant regimens offers a promising strategy to improve outcomes in HR-positive/HER2-negative eBC. While increased pCR rates are encouraging, further research with longer follow-up is necessary to establish the impact on long-term survival. Optimizing patient selection through robust predictive biomarkers and refining combination strategies will be crucial to maximize clinical benefit while minimizing toxicity.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"552-561"},"PeriodicalIF":2.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144946041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunotherapy in rare histologies of breast cancer: challenges, opportunities, and future perspectives. 罕见组织学乳腺癌的免疫治疗：挑战、机遇和未来展望。

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2025-11-01 Epub Date: 2025-08-11 DOI: 10.1097/CCO.0000000000001184

Roberta Scafetta, Marco Donato, Giuseppe Curigliano, Francesco Pantano

{"title":"Immunotherapy in rare histologies of breast cancer: challenges, opportunities, and future perspectives.","authors":"Roberta Scafetta, Marco Donato, Giuseppe Curigliano, Francesco Pantano","doi":"10.1097/CCO.0000000000001184","DOIUrl":"10.1097/CCO.0000000000001184","url":null,"abstract":"Purpose of review: Immunotherapy has transformed the management of several malignancies, yet its role in rare breast cancer histologies remains poorly defined due to limited research and few dedicated clinical trials. This review critically assesses current knowledge and emerging opportunities for immunotherapy in these uncommon breast cancer subtypes.Recent findings: Rare breast cancer histologies exhibit heterogeneous immunogenicity, including variable expression of programmed death-ligand 1 (PD-L1), differing levels of tumor-infiltrating lymphocytes (TILs), and distinct mutational burdens. Recent studies highlight potential immunotherapy responsiveness in metaplastic, invasive lobular, apocrine, and other rare breast cancer types, though predictive biomarkers like PD-L1 and tumor mutational burden (TMB) alone appear insufficient. Currently, only two clinical trials specifically target rare breast cancer histologies, emphasizing significant knowledge gaps.Summary: The effectiveness of immunotherapy in rare breast cancer histologies remains limited, likely due to inadequate patient selection using current biomarkers such as PD-L1 and TMB. Further research must focus on refining predictive biomarkers to better identify patients likely to from immunotherapy and enhance outcomes in these challenging clinical settings.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"570-579"},"PeriodicalIF":2.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144946039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of menin inhibitors in acute myeloid leukemia. menin抑制剂在急性髓性白血病中的作用。

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2025-11-01 Epub Date: 2025-08-07 DOI: 10.1097/CCO.0000000000001185

Alessandro Isidori, Giovanni Marconi

{"title":"The role of menin inhibitors in acute myeloid leukemia.","authors":"Alessandro Isidori, Giovanni Marconi","doi":"10.1097/CCO.0000000000001185","DOIUrl":"10.1097/CCO.0000000000001185","url":null,"abstract":"Purpose of review: Acute myeloid leukemia (AML) characterized by NPM1 mutations or KMT2A rearrangements depends on abnormal epigenetic programs mediated by menin, a critical scaffold protein for sustaining the expression of oncogenic HOX/MEIS1 genes. Therefore, menin inhibitors have become a promising class of AML treatments.Recent findings: Early-phase trials have shown that agents such as revumenib, ziftomenib, bleximenib, and enzomenib are active, particularly in relapsed/refractory disease, with 23-48% of patients achieving composite complete remission. However, the durability of single-agent treatment remains limited, and resistance mechanisms, such as MEN1 mutations or transcriptional reprogramming, have been identified. Consequently, combination approaches involving venetoclax, hypomethylating agents, or chemotherapy are being investigated to improve response depth and duration. Recent SAVE, KOMET-007, and cAMeLot-2 trials have demonstrated high overall response rates (68%-100%) and encouraging MRD-negative complete remissions when combining menin inhibitors with venetoclax-based regimens. This has been observed even in patients who have previously received venetoclax. Combinations with intensive chemotherapy (e.g., 7 + 3) in the frontline setting have also yielded high CRc rates (up to 94% in NPM1-mutated AML) without exacerbating toxicity.Summary: These findings justify the integration of menin inhibitors into the AML therapeutic landscape, and support ongoing randomized trials to confirm their benefit in both frontline and relapse or refractory settings.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"641-649"},"PeriodicalIF":2.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New therapies for brain metastases: an update. 脑转移的新疗法：最新进展。

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2025-11-01 Epub Date: 2025-09-05 DOI: 10.1097/CCO.0000000000001195

Marie Porte, Christophe Massard

{"title":"New therapies for brain metastases: an update.","authors":"Marie Porte, Christophe Massard","doi":"10.1097/CCO.0000000000001195","DOIUrl":"10.1097/CCO.0000000000001195","url":null,"abstract":"Purpose of review: Brain metastases occur in nearly 20% of all patients with cancer, with a rising incidence in recent years, partly due to improved systemic therapies that have prolonged survival. Traditionally managed with local approaches such as surgery, whole-brain radiotherapy (WBRT), or stereotactic radiosurgery (SRT), the therapeutic landscape has been significantly transformed by the advent of targeted therapies, immune checkpoint inhibitors, and antibody-drug-conjugates (ADCs).Recent findings: While symptomatic lesions often require local treatment, asymptomatic or oligosymptomatic brain metastases - especially in molecularly defined subgroups - may benefit from upfront systemic therapy. Significant intracranial efficacy has been demonstrated in nonsmall cell lung cancer (NSCLC) with oncogenic drivers treated with tyrosine kinase inhibitor (TKIs), in HER2-positive breast cancer with TKIs and ADCs, and in melanoma with dual immune checkpoint blockade or BRAF/MEK inhibitors. While these therapies have substantially improved intracranial disease control, the survival outcomes remain suboptimal and the optimal sequencing or combination of systemic therapy and local treatments such as SRT is yet to be defined. Several ongoing trials are exploring these strategies with promising early results, warranting further investigation.Summary: The therapeutic landscape of brain metastases has recently been transformed by the emergence of central nervous system (CNS)-penetrant systemic therapies. These advances underscore the need for updated clinical practice guidelines to optimize the overall management of patients with brain metastases.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"611-617"},"PeriodicalIF":2.4,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145198619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chimeric antigen receptor T-cell therapy in aggressive lymphomas. 嵌合抗原受体t细胞治疗侵袭性淋巴瘤。

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2025-09-01 Epub Date: 2025-07-02 DOI: 10.1097/CCO.0000000000001172

Gilles Crochet, Marc André, Wivine Bernard

{"title":"Chimeric antigen receptor T-cell therapy in aggressive lymphomas.","authors":"Gilles Crochet, Marc André, Wivine Bernard","doi":"10.1097/CCO.0000000000001172","DOIUrl":"10.1097/CCO.0000000000001172","url":null,"abstract":"Purpose of review: This review provides the latest update on chimeric antigen receptor (CAR) T-cell therapy in diffuse large B-cell lymphoma (DLBCL), as of April 2025, with a focus on specific patient populations, long-term toxicities, and the optimal sequencing of therapies, particularly in view of emerging treatments such as bispecific antibodies.Recent findings: Currently, three autologous CAR T-cell therapies targeting CD19 (axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel) have been approved for third-line treatment of DLBCL, demonstrating durable complete remission rates of up to 40%. More recently, axicabtagene ciloleucel and lisocabtagene maraleucel have been approved for second-line therapy in refractory or early-relapsed DLBCL. Additionally, the emergence of CD20/CD3 bispecific antibodies has expanded therapeutic options for relapsed/refractory DLBCL, raising questions about the optimal sequencing of these therapies. Growing real-world evidence further supports the efficacy of CAR T-cell therapy in specific populations, including elderly patients, patients with transformed indolent B-cell non-Hodgkin lymphoma, and those with Richter's transformation. Finally, extended follow-up periods have allowed for a better characterization of the long-term toxicities associated with CAR T-cell therapy.Summary: Recent data on CAR T-cell therapy in DLBCL provides valuable insights into its benefits for specific populations, the optimization of treatment sequencing, and the management of long-term toxicities.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"433-440"},"PeriodicalIF":2.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144625506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Circulating tumor DNA in B cell lymphomas. B细胞淋巴瘤循环肿瘤DNA。

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2025-09-01 Epub Date: 2025-07-02 DOI: 10.1097/CCO.0000000000001178

Marco Fangazio, Laurent Dewispelaere

{"title":"Circulating tumor DNA in B cell lymphomas.","authors":"Marco Fangazio, Laurent Dewispelaere","doi":"10.1097/CCO.0000000000001178","DOIUrl":"10.1097/CCO.0000000000001178","url":null,"abstract":"Purpose of review: This review evaluates the importance of circulating tumor DNA (ctDNA) as a minimally invasive tool in lymphoma management.Recent findings: Current literature demonstrates ctDNA's ability to alleviate the shortcomings of standard biopsy and imaging, providing real-time insights into tumor burden, clonal evolution, and treatment resistance. In Hodgkin lymphoma, ctDNA allows for comprehensive genomic profiling and treatment monitoring. In diffuse large B-cell lymphoma (DLBCL), ctDNA correlates with disease burden and is valuable for tracking resistance, especially in CAR T-cell therapy. In rare subtypes like primary central nervous system lymphoma (PCNSL) and intravascular large B-cell lymphoma (IVLBCL), ctDNA enhances diagnostic precision and enables early relapse detection. Even in indolent lymphomas, ctDNA could prove useful in relapse monitoring and risk assessment.Summary: CtDNA analysis could become a key element in personalized lymphoma management, enabling earlier interventions and tailored treatment strategies. However, future efforts should focus on harmonizing methodologies and validating findings in large-scale trials to allow these techniques to be adopted in routine practice.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"408-413"},"PeriodicalIF":2.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144625507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mantle cell lymphoma: how to clarify the confusion around first-line treatment? 套细胞淋巴瘤：如何澄清一线治疗的困惑？

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2025-09-01 Epub Date: 2025-07-04 DOI: 10.1097/CCO.0000000000001177

Morgane Cheminant, Elena Robin-Marieton

{"title":"Mantle cell lymphoma: how to clarify the confusion around first-line treatment?","authors":"Morgane Cheminant, Elena Robin-Marieton","doi":"10.1097/CCO.0000000000001177","DOIUrl":"10.1097/CCO.0000000000001177","url":null,"abstract":"Purpose of review: First-line treatment strategies for mantle cell lymphoma (MCL) have greatly improved in recent years. High dose cytarabine, autologous stem cell transplantation for eligible patients and anti-CD20 maintenance therapy for all patients, have contributed to enhanced results, establishing a standard of care with unprecedented long-term outcome. Recently, a growing number of effective options such as Bruton's tyrosine kinase (BTK) inhibitors, combinations of targeted therapies, and immunotherapies, have emerged, leading to confusion regarding the optimal first-line approach.Recent findings: BTK inhibitors have reshaped MCL treatment landscape, optimizing outcomes and minimizing toxicity. They will now be essential to first-line treatment strategy for young patients, challenging the traditional role of autologous stem cell transplantation. Moreover, targeted therapies have opened new prospects on chemo-free treatments for older patients.Summary: The variety of treatment options will enable tailoring therapy. Prognostic stratification at diagnosis is crucial, paving the way for personalized treatment. This underscores the need for clear guidelines to navigate the complexities of available therapies and ensure effective treatment selection.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"401-407"},"PeriodicalIF":2.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144575009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel molecular imaging approaches in oncology: towards a more accurate estimation of tumour response. 新的分子成像方法在肿瘤学：朝着更准确的估计肿瘤反应。

IF 2.4 4区医学

Current Opinion in Oncology Pub Date : 2025-09-01 Epub Date: 2025-07-09 DOI: 10.1097/CCO.0000000000001166

Amy Rose Sharkey, Anum Pervez, Gary J R Cook

{"title":"Novel molecular imaging approaches in oncology: towards a more accurate estimation of tumour response.","authors":"Amy Rose Sharkey, Anum Pervez, Gary J R Cook","doi":"10.1097/CCO.0000000000001166","DOIUrl":"10.1097/CCO.0000000000001166","url":null,"abstract":"Purpose of review: With novel therapeutics improving cancer survival rates, the need for accurate treatment response assessment has become increasingly crucial. The Response Evaluation Criteria in Solid Tumours remains the standard imaging method for evaluation of treatment response, yet it has recognized limitations. Molecular imaging with targeted tracers offers earlier and more precise assessment of treatment efficacy, by capturing biological information beyond a change in tumour size. We discuss these recent advances, including tracers in clinical practice, and novel tracers in the pipeline, and how these can improve our assessment of treatment response.Recent findings: The development of novel tracers is enabling more precise cancer diagnosis, staging and treatment, and enables the use of targeted treatments. Upcoming tracers offer the potential to predict treatment response prior to treatment, eradicating the morbidity associated with ineffective therapy. Improved PET hardware, such as total body PET, allows accurate insights into factors such as tumour uptake kinetics, which can be paired with artificial intelligence tools to allow prediction of tumour characteristics.Summary: This review summarizes recent advances in molecular imaging, including tracers that target tumour metabolism, tumour microenvironment and other treatable tumour targets. These aim to improve treatment response assessment, with the hope of improving outcomes by offering personalized and timely treatment adjustments.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"522-528"},"PeriodicalIF":2.4,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12337909/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144599688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0